Catecholaminergic Polymorphic Ventricular Tachycardia
Cardiovascular·MeSH: Polymorphic Catecholaminergic Ventricular Tachycardia
Prevalence
30.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| SGT-501 | Solid Biosciences Inc. (SLDB) |
Frequently asked questions
How many drugs are in development for Catecholaminergic Polymorphic Ventricular Tachycardia?
BioSniper tracks 1 drug in development for Catecholaminergic Polymorphic Ventricular Tachycardia across 1 company.
How many clinical trials target Catecholaminergic Polymorphic Ventricular Tachycardia?
There are 2 clinical trials targeting Catecholaminergic Polymorphic Ventricular Tachycardia tracked by BioSniper.
What is the prevalence of Catecholaminergic Polymorphic Ventricular Tachycardia?
The estimated prevalence of Catecholaminergic Polymorphic Ventricular Tachycardia is approximately 30.0 per 100,000 population.
Deep-dive into Catecholaminergic Polymorphic Ventricular Tachycardia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis